Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What is the Projected CAGR for the Low-Grade Glioma Market Size from 2025 to 2034?
In recent years, there has been significant growth in the market size of low-grade glioma. An increase from $1.39 billion in 2024 to $1.48 billion in 2025 is projected, implying a compound annual growth rate (CAGR) of 6.1%. The growth witnessed in the past can be credited to the heightened awareness of brain tumors, the rise in oncology-centered funding which promotes research, the surge in the designation of orphan drugs, the broadening scope of telemedicine, and heightened healthcare accessibility.
Expectations are high for a robust expansion of the low-grade glioma market in the coming years. The market’s projected rise to $1.86 billion in 2029, representing a compound annual growth rate (CAGR) of 5.9%, signals this. A number of factors will contribute to this growth over the forecast period including an increase in the elderly population, heightened spending on healthcare, a surge in brain tumor cases, escalating government interventions, and an uptick in the incidence and prevalence of high-grade gliomas. The prediction period will also see significant trends such as advancements in imaging technologies, the evolution of radiation therapies, debut of new chemotherapy regimens, proliferation of clinical trials, and the inclusion of immunotherapy.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21215&type=smp
What are the Fundamental Drivers and Innovations Shaping the Low-Grade Glioma Market?
The surge in brain tumor cases is anticipated to spur the expansion of the low-grade glioma market in the future. Brain tumors, categorized as benign or malignant, emerge from unusual cell growth in the brain or its nearby regions. Exposure to radiation, environmental contaminants, genetic susceptibility, and aging are primary factors contributing to the rising incidence of brain tumors. Low-grade glioma plays a crucial role in treating brain tumors by employing innovative diagnostic methods and specific therapies including surgery, radiation, and chemotherapy. These methods slow tumor growth, conserve neurological function, and enhance patient outcomes, underscoring the importance of early detection and individualized treatment in managing other brain tumors with similar growth patterns. For example, in 2023, The Central Brain Tumor Registry of the United States (CBTRUS), reported that the global incidence rate of primary malignant brain tumors in 2022 was about 3.5 per 100,000. The prevalence was higher in high-income countries (4.9 per 100,000) compared to middle-low income (2.4 per 100,000) and low-income countries. As a result of the increasing incidence of brain tumors, there has been substantial growth in the low-grade glioma market.
How Is the Low-Grade Glioma Market Segmented?
The low-grade glioma market covered in this report is segmented –
1) By Drug Type: Trametinib, Dabrafenib, Ivosidenib, Mirdametinib
2) By Treatment: Surgery, Chemotherapy, Radiation
3) By Route Of Administration: Topical, Oral
4) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21215&type=smp
Which Regions Are Driving the Next Phase of the Low-Grade Glioma Market Growth?
North America was the largest region in the low-grade glioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the low-grade glioma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Trends Are Shaping the Future of the Low-Grade Glioma Market?
Leading corporations in the low-grade glioma market are now directing their focus towards the incorporation of both combination therapies and targeted treatment, including drugs tailored to genetic alterations, with the goal of maintaining their competitiveness and improving treatment options for children suffering from low-grade glioma. Drugs designed to alter genetics are targeted treatments created to either modify or suppress specific genetic mutations or cell abnormalities, thus effectively treating illnesses such as cancer by halting the mechanisms that trigger unchecked cell growth. For example, in May 2024, Day One Biopharmaceuticals, a firm based in the United States, introduced Tovorafenib (Ojemda) after receiving accelerated approval from the FDA. Formulated to cater to children who are at least six months old and who have unresectable or recurring low-grade glioma (LGG) with BRAF gene alterations, this targeted treatment offers a convenient weekly oral medication, thus meeting a critical need for pediatric LGG patients who had fewer prior treatment choices.
View the full report here:
https://www.thebusinessresearchcompany.com/report/low-grade-glioma-global-market-report
How Is the Low-Grade Glioma Market Defined and What Are Its Core Parameters?
Low-grade gliomas are a type of brain tumor that develops from glial cells, which provide support and insulation to nerve cells in the brain, characterized by slow growth and generally less aggressive behavior compared to high-grade gliomas, though they can still cause significant neurological symptoms and may require treatments.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21215
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model